Logo

OKUR

OnKure Therapeutics, Inc.

OKUR

OnKure Therapeutics, Inc. • NASDAQ
$3.01 ▲ 5.24% (+0.15)
Market Cap $40.78 M
52w High $15.89
52w Low $1.70
Dividend Yield 0%
P/E -0.64
Volume 52.77K
Outstanding Shares 13.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $15.501M ▼ $-14.699M ▲ 0% $0 ▲ $-14.493M ▲
Q2-2025 $0 $16.324M ▼ $-15.39M ▲ 0% $-1.14 ▲ $-15.178M ▲
Q1-2025 $0 $17M ▼ $-15.925M ▲ 0% $-1.19 ▲ $-16.788M ▲
Q4-2024 $0 $33.795M ▲ $-35.194M ▼ 0% $-2.64 ▼ $-31.16M ▼
Q3-2024 $0 $4.66M $-3.692M 0% $-0.28 $-3.68M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $70.331M ▼ $72.835M ▼ $6.407M ▼ $66.428M ▼
Q2-2025 $83.374M ▼ $86.07M ▼ $7.904M ▼ $78.166M ▼
Q1-2025 $96.661M ▼ $99.882M ▼ $9.234M ▼ $90.648M ▼
Q4-2024 $110.761M ▲ $114.907M ▲ $11.079M ▲ $103.828M ▲
Q3-2024 $76.668M $77.645M $3.627M $74.018M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-14.699M ▲ $-13.037M ▲ $-6K ▲ $0 $-13.043M ▲ $-13.043M ▲
Q2-2025 $-15.39M ▲ $-13.274M ▲ $-13K ▲ $0 ▲ $-13.287M ▲ $-13.287M ▲
Q1-2025 $-15.925M ▲ $-14.005M ▲ $-18K ▲ $-77K ▼ $-14.1M ▼ $-14.023M ▲
Q4-2024 $-35.194M ▼ $-21.015M ▼ $-45.375M ▼ $114.218M ▲ $50.072M ▲ $-21.065M ▼
Q3-2024 $-11.556M $-10.661M $-18K $5K $-10.674M $-10.679M

Five-Year Company Overview

Income Statement

Income Statement OKUR is a classic early-stage biotech story: no product revenue yet and a steady pattern of operating losses as it funds research and clinical trials. Losses have been fairly consistent over the past several years, reflecting a focused but ongoing investment in development rather than any sign of commercial scale. Earnings per share look volatile, but that mainly reflects changes in share count and capital structure, not big swings in the underlying business. Overall, the income statement shows a company still firmly in the “build and test” phase, not yet in the “sell and earn” phase.

Balance Sheet

Balance Sheet The balance sheet is lean and dominated by cash, with very little in the way of fixed assets. Debt that existed earlier has been eliminated, which reduces financial risk but puts more emphasis on equity funding. Equity has swung between negative and positive over the years, pointing to recapitalizations and the impact of accumulated losses, with the recent merger and financing improving the picture. The reverse stock split in 2024 is a capital-markets move, often used to meet listing standards, and doesn’t change the underlying economics. In short, OKUR has a simple, cash-heavy, but relatively small balance sheet typical of a niche clinical-stage biotech.

Cash Flow

Cash Flow Cash flows are straightforward: money is flowing out to fund operations and clinical work, with no offsetting product inflows yet. Operating cash outflows closely match free cash flow, since capital spending is minimal; this underscores that most cash goes directly into R&D, trials, and overhead, not into large facilities. The recent capital raise linked to the Reneo transaction provides a multi-year runway, but the company remains dependent on external funding until it can secure partnerships, non-dilutive funding, or eventual product revenues. The key watch-point is how efficiently OKUR converts this cash burn into clinical progress and value-creating data.

Competitive Edge

Competitive Edge Competitively, OKUR is positioned as a specialist in precision oncology, targeting specific cancer mutations with high-selectivity small molecules. Its focus on PI3Kα and HDAC targets is in crowded spaces that include major pharma players, but OKUR is trying to differentiate through tighter selectivity, better tolerability, and biomarker-driven patient selection. The team’s experience in kinase inhibition and a focused intellectual property portfolio provide some protection, though larger competitors have more resources and broader pipelines. Targeting well-defined genetic subsets and niche indications can help OKUR carve out a space, but commercial success will hinge on proving clearly better efficacy and safety versus entrenched drugs.

Innovation and R&D

Innovation and R&D Innovation is the core of OKUR’s story. The structure-based drug design platform is aimed at building highly selective inhibitors, which, if successful, can translate into more effective and safer cancer treatments. The lead PI3Kα mutant inhibitor, OKI-219, and the HDAC inhibitor, OKI-179, are both designed to improve on existing classes by narrowing off-target effects and improving tolerability. Pipeline depth is still limited but focused, with additional next-generation PI3Kα programs in the wings and a strategy that includes combination therapies and expansion into non-oncology indications like vascular malformations. The main risk is typical for this stage: high scientific and clinical uncertainty, with value heavily concentrated in a small number of key trials and readouts.

Summary

Overall, OKUR is an early-stage, research-driven oncology company with no revenues yet, consistent losses, and a balance sheet that has recently been strengthened through transactions and financing. Its value proposition rests almost entirely on its ability to turn a focused precision-oncology platform into successful clinical outcomes, particularly for OKI-219 and OKI-179. The company operates in highly competitive therapeutic areas but is aiming for an edge through selective targeting, biomarker-driven development, and combination strategies. For observers, the critical milestones to monitor will be clinical data quality, safety profiles versus existing drugs, cash runway versus burn rate, and the company’s ability to attract partnerships or additional funding on favorable terms.

NEWS

November 6, 2025 · 4:03 PM UTC

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

Read more

November 4, 2025 · 4:05 PM UTC

OnKure Therapeutics to Participate in Upcoming Investor Conferences

Read more